These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 28507806)

  • 1. Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.
    Garg AD; Vandenberk L; Van Woensel M; Belmans J; Schaaf M; Boon L; De Vleeschouwer S; Agostinis P
    Oncoimmunology; 2017; 6(4):e1295903. PubMed ID: 28507806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
    Shen S; Chen L; Liu J; Yang L; Zhang M; Wang L; Zhang R; Uemura Y; Wu Q; Yu X; Liu T
    Cancer Biol Med; 2020 Aug; 17(3):555-568. PubMed ID: 32944390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
    Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
    Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg
    Zhai L; Ladomersky E; Lauing KL; Wu M; Scholtens DM; Savoor R; Zhang B; Wu JD; Horbinski C; Lukas RV; Binder DC; Wainwright DA
    Oncoimmunology; 2019; 8(3):1548242. PubMed ID: 30723577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
    Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
    Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
    Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
    Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
    Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
    Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies.
    Maung TZ; Ergin HE; Javed M; Inga EE; Khan S
    Cureus; 2020 May; 12(5):e8095. PubMed ID: 32542150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
    Jessurun CAC; Vos JAM; Limpens J; Luiten RM
    Front Oncol; 2017; 7():233. PubMed ID: 29034210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.
    Crosby EJ; Wei J; Yang XY; Lei G; Wang T; Liu CX; Agarwal P; Korman AJ; Morse MA; Gouin K; Knott SRV; Lyerly HK; Hartman ZC
    Oncoimmunology; 2018; 7(5):e1421891. PubMed ID: 29721371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
    Mason NJ; Chester N; Xiong A; Rotolo A; Wu Y; Yoshimoto S; Glassman P; Gulendran G; Siegel DL
    MAbs; 2021; 13(1):2004638. PubMed ID: 34856888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor.
    Bai X; Yi M; Jiao Y; Chu Q; Wu K
    Onco Targets Ther; 2019; 12():9527-9538. PubMed ID: 31807028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors.
    Bertucci F; Boudin L; Finetti P; Van Berckelaer C; Van Dam P; Dirix L; Viens P; Gonçalves A; Ueno NT; Van Laere S; Birnbaum D; Mamessier E
    Oncoimmunology; 2021 May; 10(1):1929724. PubMed ID: 34104544
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.